Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will be featured in HighRes’ Lightning Talk at the NVIDIA GTC AI ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the AI stocks that will go to the moon. On February 18, Recursion ...
Nvidia disclosed in recent regulatory filings that it had fully exited its roughly two‑year, 7.71 million‑share investment in Recursion Pharmaceuticals, while Cathie Wood’s ARK Invest simultaneously ...
Recursion Pharmaceuticals Inc RXRX shares are under pressure Wednesday after new regulatory filings showed that Nvidia Corp NVDA has fully exited its investment in the AI‑focused drug‑discovery ...
Don't call Recursion Pharmaceuticals (NASDAQ: RXRX) a biotech company. Its management prefers the term "TechBio." While many have been skeptical about TechBio in the past, the reception is changing ...
We believe that Recursion RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is likely to beat expectations when it reports second-quarter 2024 results. The ...
Recursion will host a (L)earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion’s X, LinkedIn, and YouTube accounts.
Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) stock sinks as market gains: What you should know
Recursion Pharmaceuticals (RXRX) closed at $3.42 in the latest trading session, marking a -8.06% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.69%.
Chris Gibson, PhD, Recursion’s co-founder and CEO, discusses exclusively with GEN Edge his company’s ambitious plans to develop 100 pipeline candidates in roughly a decade, the savings in money and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results